ESMO Congress 2022
![Venue_external_entrance](/var/esmo/storage/images/media/esmo-daily-reporter/images/esmo-congress-2022/onsite/venue_external_entrance/12224714-1-eng-GB/venue_external_entrance_i770.jpg)
A transcriptomic signature can identify gemcitabine-sensitive patients with pancreatic cancer
Disease-free and overall survival in the PRODIGE-24/CCTG PA6 study were significantly higher in GemPred-positive versus GemPred-negative patients who received adjuvant gemcitabine
![Poster area_generic](/var/esmo/storage/images/media/esmo-daily-reporter/images/esmo-congress-2022/onsite/poster-area_generic2/12226265-1-eng-GB/poster-area_generic_i770.jpg)
Pathogenic variants in HRR genes can be a risk factor for anthracycline-induced cardiotoxicity
A study presented at ESMO Congress 2022 highlights the need to identify predictors of anticancer drug toxicity as more complex treatments become available
![Poster area_generic](/var/esmo/storage/images/media/esmo-daily-reporter/images/esmo-congress-2022/onsite/poster-area_generic/12226142-1-eng-GB/poster-area_generic_i770.jpg)
Are we getting closer to apply AI-based techniques in clinical practice?
AI technology is being tested across tumour types and with different purposes, with an emerging trend for adding value to whole slide image analyses for HER2 status
![John Haanen](/var/esmo/storage/images/media/esmo-daily-reporter/images/portraits/john-haanen/12206006-1-eng-GB/john-haanen_i770.jpg)
Has TIL therapy the potential to change cancer treatment?
After TILs have shown benefits in advanced melanoma, many ‘synthetic biology’ strategies can be conceived to potentially extend this clinical signal to other patient groups
![Garon_PP_lung_11.09](/var/esmo/storage/images/media/esmo-daily-reporter/images/esmo-congress-2022/onsite/garon_pp_lung_11.09/12230906-1-eng-GB/garon_pp_lung_11.09_i770.jpg)
Lack of clinical benefit with adjuvant canakinumab in completely resected NSCLC
Negative results from the CANOPY-A trial do not support use in the adjuvant setting
![Bardia_PP_11.09](/var/esmo/storage/images/media/esmo-daily-reporter/images/esmo-congress-2022/onsite/bardia_pp_11.09/12230603-1-eng-GB/bardia_pp_11.09_i770.jpg)
PRO data support the use of antibody–drug conjugates in metastatic breast cancer
Patient-reported data from the DESTINY-BREAST04 and TROPiCS-02 trials may help improve current knowledge of quality of life on long-term treatment
![Kasper_Presidential I_10.09](/var/esmo/storage/images/media/esmo-daily-reporter/images/esmo-congress-2022/onsite/kasper_presidential-i_10.09/12215687-3-eng-GB/kasper_presidential-i_10.09_i770.jpg)
First positive phase III data for a gamma secretase inhibitor in desmoid tumours
Nirogacestat improves progression-free survival in a randomised trial performed in desmoid tumours
![Haanen_Presidential_10.09](/var/esmo/storage/images/media/esmo-daily-reporter/images/esmo-congress-2022/onsite/haanen_presidential_10.09/12213749-3-eng-GB/haanen_presidential_10.09_i770.jpg)
TILs confirm to prolong PFS compared with immunotherapy in advanced melanoma
In a head-to-head comparison to the standard of care, tumour-infiltrating lymphocytes show clinical efficacy even in patients who are refractory to anti-PD-1 treatment
![Swanton_Presidential_10.09](/var/esmo/storage/images/media/esmo-daily-reporter/images/esmo-congress-2022/onsite/swanton_presidential_10.09/12213518-2-eng-GB/swanton_presidential_10.09_i770.jpg)
A pathway from air pollution to lung cancer in non-smokers has been identified
In a study presented at ESMO Congress 2022, air pollution is shown to drive interleukin-1β release in cells with EGFR mutations to promote lung cancer development
![Public_generic](/var/esmo/storage/images/media/esmo-daily-reporter/images/esmo-congress-2022/onsite/public_generic/12216698-1-eng-GB/public_generic_i770.jpg)
Next-generation sequencing can identify molecular alterations in glioma: are we ready for targeted treatments?
Three studies support the use of NGS to better understand the molecular drivers of this brain tumour, but effective targeted treatments are still lacking